Muna Therapeutics

About Muna Therapeutics

Muna Therapeutics is focused on discovering and developing therapies to slow or stop devastating neurodegenerative diseases such as Alzheimer's and Parkinson's, with a bold vision of resilience.

Products & Services

Novel Oral TREM2 Agonist:A therapy under development for early Alzheimer's Disease, currently in Phase 1 clinical trials.

Treatments for Alzheimer's Disease:Novel treatments being developed in collaboration with GSK to accelerate progress in addressing Alzheimer's Disease.

Specialties

Neurology Drug Discovery Neurodegenerative Disease Therapies Alzheimer's Disease Treatment Parkinson's Disease Treatment

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Grant T: - FT: Grant	A: 1000000 MR: - FA: $1 million FAN: 1000000	D: 2026-01-08 FD: 2026-01-08	1 investors

Grant Latest

2026-01-08

$1.0M

1 investor (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

L

Liesbeth DeLange

Principal Investigator, Predictive Pharmacology, Division of Systems Biomedicine and Pharmacology, Leiden Academic Center for Drug Research, Leiden University, The Netherlands

M

Malcolm McCoss

Visiting Professor of Chemistry for Medicine, University of Oxford, Oxford, UK and Founder, Bohicket Pharma Consulting, LLC

D

David Witty

Vice President of Chemistry and IP, Eliem Therapeutics; Co-Founder and Director, WITNET, Ltd

B

Bart De Strooper

Chief Scientific Advisor and Chair of the Scientific Advisory Board

S

Simon Glerup

Professor of Biomedicine

P

Philip Van Damme

Professor of Neurology and Neuroscience, Vlaams Instituut voor Biotechnologie (VIB), Belgium and the Katholieke Universiteit Leuven (KU Leuven)

View 31 more team members with Pro

Unlock Full Team Directory

Recent News